Partial Reduction in BRCA1 Gene Dose Modulates DNA Replication Stress Level and Thereby Contributes to Sensitivity or...

Area of Science:

• Genetics
• Molecular Biology
• Cancer Research

Background:

• BRCA1 is a critical breast cancer risk gene involved in DNA repair.
• Therapy resistance in breast cancer is often linked to BRCA1 gene alterations.
• The role of mutations in non-functional BRCA1 domains in therapy resistance is not well understood.

Purpose of the Study:

• To investigate how mutations in non-functional domains of BRCA1 affect DNA repair and therapy sensitivity in breast cancer.
• To analyze the impact of BRCA1 exon 9 and 14 indels on homologous recombination (HR) and replication stress (RS).

Main Methods:

• CRISPR/Cas9 gene editing was used to generate MCF7 cell lines with BRCA1 mutations.
• Evaluated HR capacity, response to replication stress, and sensitivity to Mitomycin C (MMC), PARP1 inhibition, and ionizing radiation.

Main Results:

• BRCA1 mutations led to reduced HR capacity but paradoxically caused both increased sensitivity and resistance to DNA damage.
• Resistance was linked to enhanced DNA double-strand break repair and reduced replication stress.
• Lower replication stress correlated with increased activation of S phase DNA damage response proteins like FANCD2 and CHK1.

Conclusions:

• Mutations in non-functional BRCA1 domains can confer complex resistance mechanisms to DNA damaging agents.
• Understanding these mechanisms is crucial for developing targeted breast cancer therapies.
• BRCA1's role in replication stress response is critical for therapeutic outcomes.